Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab in Early Alzheimer's Disease
NCT02484547Phase 3Terminated
- Sponsor
- Biogen
- Start
- Sep 2015
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of aducanumab in Alzheimer's disease (AD), sponsored by Biogen. Started Sep 2015; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02484547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484547.